Education
About Us
Working with TipRanks
Follow Us
Aligos Therapeutics (ALGS)
NASDAQ:ALGS
Total Valuation
Aligos Therapeutics has a market cap or net worth of $45.74M. The enterprise value is -$41.55M.
Market Cap$45.74M
Enterprise Value-$41.55M
Share Statistics
Aligos Therapeutics has 5,351,374 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,351,374
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Aligos Therapeutics’s return on equity (ROE) is 4.53 and return on invested capital (ROIC) is -172.50%.
Return on Equity (ROE)4.53
Return on Assets (ROA)-1.87
Return on Invested Capital (ROIC)-172.50%
Return on Capital Employed (ROCE)-1.84
Revenue Per Employee56.36K
Profits Per Employee-1.87M
Employee Count70
Asset Turnover0.06
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aligos Therapeutics is ―. Aligos Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value-8.61
Price to FCF―
Price to Operating Cash Flow-1.06
PEG Ratio―
Income Statement
In the last 12 months, Aligos Therapeutics had revenue of 3.94M and earned -131.21M in profits. Earnings per share was -20.94.
Revenue3.94M
Gross Profit3.94M
Operating Income-89.15M
Pretax Income-130.88M
Net Income-131.21M
EBITDA-89.15M
Earnings Per Share (EPS)-20.94
Cash Flow
In the last 12 months, operating cash flow was -74.92M and capital expenditures -206.00K, giving a free cash flow of -75.12M billion.
Operating Cash Flow-74.92M
Free Cash Flow-75.12M
Free Cash Flow per Share-14.04
Dividends & Yields
Aligos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.81
52-Week Price Change-36.25%
50-Day Moving Average7.90
200-Day Moving Average15.24
Relative Strength Index (RSI)45.76
Average Volume (3m)73.96K
Important Dates
Aligos Therapeutics upcoming earnings date is Oct 30, 2025, After Close (Confirmed).
Last Earnings DateAug 6, 2025
Next Earnings DateOct 30, 2025
Ex-Dividend Date―
Financial Position
Aligos Therapeutics as a current ratio of 2.86, with Debt / Equity ratio of 6.75%
Current Ratio2.86
Quick Ratio2.86
Debt to Market Cap0.03
Net Debt to EBITDA0.32
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aligos Therapeutics has paid 331.00K in taxes.
Income Tax331.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Aligos Therapeutics EV to EBITDA ratio is -2.48, with an EV/FCF ratio of -2.73.
EV to Sales56.01
EV to EBITDA-2.48
EV to Free Cash Flow-2.73
EV to Operating Cash Flow-2.74
Balance Sheet
Aligos Therapeutics has $123.06M in cash and marketable securities with $6.88M in debt, giving a net cash position of -$116.18M billion.
Cash & Marketable Securities$123.06M
Total Debt$6.88M
Net Cash-$116.18M
Net Cash Per Share-$21.71
Tangible Book Value Per Share-$4.62
Margins
Gross margin is 70.70%, with operating margin of -2259.92%, and net profit margin of -3326.01%.
Gross Margin70.70%
Operating Margin-2259.92%
Pretax Margin-3317.62%
Net Profit Margin-3326.01%
EBITDA Margin-2259.92%
EBIT Margin-2259.92%
Analyst Forecast
The average price target for Aligos Therapeutics is $7.50, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$7.50
Price Target Upside-1.96% Downside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast-60.16%
EPS Growth Forecast―